Interactions in cancer treatment considering cancer therapy, concomitant medications, food, herbal medicine and other supplements

GND
1277655677
ORCID
0000-0002-5429-2008
Zugehörigkeit
Klinik für Innere Medizin II, Hämatologie und Internistische Onkologie, Universitätsklinikum Jena, Jena, Germany
Wolf, Clemens P. J. G.;
GND
1018243313
Zugehörigkeit
Klinik für Innere Medizin II, Hämatologie und Internistische Onkologie, Pneumologie, Universitätsklinikum Jena, Jena, Germany
Rachow, Tobias;
GND
129357685
Zugehörigkeit
Klinik für Innere Medizin II, Hämatologie und Internistische Onkologie, Konservative Tagesklinik des UniversitätsTumorCentrums (UTC), Universitätsklinikum Jena, Jena, Germany
Ernst, Thomas;
GND
1107039339
Zugehörigkeit
Klinik für Innere Medizin II, Hämatologie und Internistische Onkologie, Universitätsklinikum Jena, Jena, Germany
Hochhaus, Andreas;
GND
123786363
Zugehörigkeit
Onkologische Kooperation Harz, Goslar, Germany
Zomorodbakhsch, Bijan;
GND
1270828711
Zugehörigkeit
Klinik für Urologie, Universitätsklinikum Jena, Jena, Germany
Foller, Susan;
GND
1312100443
Zugehörigkeit
Klinik und Poliklinik für Frauenheilkunde und Fortpflanzungsmedizin, Universitätsklinikum Jena, Jena, Germany
Rengsberger, Matthias;
GND
123079640
Zugehörigkeit
Apotheke des Universitätsklinikums, Universitätsklinikum Jena, Jena, Germany
Hartmann, Michael;
GND
13402012X
Zugehörigkeit
Klinik für Innere Medizin II, Hämatologie und Internistische Onkologie, Integrative Onkologie, Universitätsklinikum Jena, Jena, Germany
Hübner, Jutta

Abstract Purpose The aim of our study was to analyse the frequency and severity of different types of potential interactions in oncological outpatients’ therapy. Therefore, medications, food and substances in terms of complementary and alternative medicine (CAM) like dietary supplements, herbs and other processed ingredients were considered. Methods We obtained data from questionnaires and from analysing the patient records of 115 cancer outpatients treated at a German university hospital. Drug–drug interactions were identified using a drug interaction checking software. Potential CAM-drug interactions and food–drug interactions were identified based on literature research. Results 92.2% of all patients were at risk of one or more interaction of any kind and 61.7% of at least one major drug–drug interaction. On average, physicians prescribed 10.4 drugs to each patient and 6.9 interactions were found, 2.5 of which were classified as major. The most prevalent types of drug–drug interactions were a combination of QT prolonging drugs (32.3%) and drugs with a potential for myelotoxicity (13.4%) or hepatotoxicity (10.1%). In 37.2% of all patients using CAM supplements the likelihood of interactions with medications was rated as likely. Food-drug interactions were likely in 28.7% of all patients. Conclusion The high amount of interactions could not be found in literature so far. We recommend running interaction checks when prescribing any new drug and capturing CAM supplements in medication lists too. If not advised explicitly in another way drugs should be taken separately from meals and by using nonmineralized water to minimize the risk for food–drug interactions.

Zitieren

Zitierform:
Zitierform konnte nicht geladen werden.

Rechte

Rechteinhaber: © The Author(s) 2021

Nutzung und Vervielfältigung: